17,261 trials
Thrombocytopenia
Primary: Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study — 80.0; 60.0; 58.3; 91.7 percentage of participants
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
HIV Coinfection · Aids/Hiv Problem · Tuberculosis, Pulmonary
Primary: Sputum Culture — 15; 20; 14 Participants
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Acute ST Segment Elevation Myocardial Infarction
Primary: High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure) — 106.84; 107.65; 184.30 mg*day/L
Fragile X Syndrome (FXS)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 0; 0; 0; 1 participants
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate — 3 Participants
Mantle Cell Lymphoma
Primary: Complete Response (CR) Rate at End of Induction — 28; 4; 0; 0 Participants
Breast Cancer
Primary: Mammographic Density (Baseline) — 29.21; 28.24 percentage of glandular tissue in breast
Chronic Urticaria
Primary: Change in Urticaria Control Test (UCT) Score From Baseline to Week 22 in the Main Study Phase — 6.5; 3.4; 11.1; 4.8 Score on a scale
Advanced Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessment — 7.4; 2.0 Months
Kidney Transplant Recipients
Primary: Proportion of Recipients Who Achieve an Antibody Response >50 U/mL After the Third Dose of mRNA COVID-19 Vaccine — 69.1 Percentage of participants with response
Lung Transplant
Primary: Percentage of Patients Remaining on Envarsus XR at 1 Year — 40 Participants
Gingivitis
Primary: Number of Bleeding Sites at 6 Weeks (Comparison of Experimental Versus Negative Control Dentifrice) — 9.5; 20.5 Number of Sites — p=<0.0001
X-Linked Retinitis Pigmentosa
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants